For that purpose a plethora of molecular methods were adapted for the identification of IDH1 and IDH2 mutations in human gliomas and myeloid malignancies such as direct DNA sequencing [6], restriction fragment length polymorphism (RFLP) gel electrophoresis[7], allele specific polymerase chain reaction (AS-PCR)[8], pyrosequencing[9], real-time PCR [10], high resolution melting (HRM)[11]–[13] curve analysis, denaturing high-performance liquid chromatography (DHPLC)[14], next generation sequencing (NGS) [15] and even immunohistochemical detection of IDH1 R132H mutant protein [8]. The gene discussed is IDH2; the disease is central nervous system cancer.